Pathways' Pick of the Week: Medtech Gets a Foothold in Drug-Dominated Spaces

article image
ARTICLE SUMMARY:

New CMS 2025 payment rules are favorable to medtech. Excerpted from Pathways’ Picks November 6: Trump Wins, Medicare Rules, and More Global Medtech Policy Updates.

CMS finalized two policies November 1 that help give medtech tools a foothold in drug-dominated clinical arenas. In one case, the agency awarded additional payments to devices that can reduce reliance on opioids. In the other, it established a reimbursement path for digital therapeutics for mental health. The policies came amid thousands of pages of rulemaking published by the Medicare agency last week, including some positive measures for imaging technologies and an array of other updates impacting payments for physicians, outpatient departments, dialysis facilities, and home health agencies. (For more details, see “Medicare for Medtech: Opioid Alternatives and Digital Therapeutics Get Paid.”)

Continue reading Pathways’ Picks here.
×



Articles from David Filmore:

Regulatory & Reimbursement

CMS Nominee: Dr. Oz

A thumbnail sketch of Donald Trump's nominee for CMS administrator: TV personality and cardiac surgeon Mehmet Oz, MD.

Read Article